[Comment on the European guidelines for use of delayed action drugs for treatment of hyperkinetic disorders]

Z Kinder Jugendpsychiatr Psychother. 2008 Mar;36(2):77-9. doi: 10.1024/1422-4917.36.2.77.
[Article in German]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Atomoxetine Hydrochloride
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Central Nervous System Stimulants / administration & dosage*
  • Central Nervous System Stimulants / adverse effects
  • Child
  • Delayed-Action Preparations
  • Europe
  • Evidence-Based Medicine*
  • Humans
  • Methylphenidate / administration & dosage
  • Methylphenidate / adverse effects
  • Practice Guidelines as Topic*
  • Propylamines / administration & dosage
  • Propylamines / adverse effects
  • Psychotherapy
  • Treatment Outcome

Substances

  • Central Nervous System Stimulants
  • Delayed-Action Preparations
  • Propylamines
  • Methylphenidate
  • Atomoxetine Hydrochloride